JP7267012B2 - 抗ｔｉｍ－３抗体及びその使用方法 - Google Patents

抗ｔｉｍ－３抗体及びその使用方法 Download PDF

Info

Publication number
JP7267012B2
JP7267012B2 JP2018561979A JP2018561979A JP7267012B2 JP 7267012 B2 JP7267012 B2 JP 7267012B2 JP 2018561979 A JP2018561979 A JP 2018561979A JP 2018561979 A JP2018561979 A JP 2018561979A JP 7267012 B2 JP7267012 B2 JP 7267012B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
seq
tim
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018561979A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019520809A5 (enExample
JP2019520809A (ja
Inventor
マルク・ファン・ダイク
エカテリーナ・ウラジーミロヴナ・ブレオウス－ニストロム
ニコラス・スチュアート・ウィルソン
ジェレミー・デイル・ワイト
デニス・ジョン・アンダーウッド
Original Assignee
アジェナス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アジェナス インコーポレイテッド filed Critical アジェナス インコーポレイテッド
Publication of JP2019520809A publication Critical patent/JP2019520809A/ja
Publication of JP2019520809A5 publication Critical patent/JP2019520809A5/ja
Priority to JP2023068767A priority Critical patent/JP7723697B2/ja
Application granted granted Critical
Publication of JP7267012B2 publication Critical patent/JP7267012B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Endocrinology (AREA)
JP2018561979A 2016-05-27 2017-05-26 抗ｔｉｍ－３抗体及びその使用方法 Active JP7267012B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023068767A JP7723697B2 (ja) 2016-05-27 2023-04-19 抗ｔｉｍ－３抗体及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662342610P 2016-05-27 2016-05-27
US62/342,610 2016-05-27
US201662420276P 2016-11-10 2016-11-10
US62/420,276 2016-11-10
PCT/US2017/034645 WO2017205721A1 (en) 2016-05-27 2017-05-26 Anti-tim-3 antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023068767A Division JP7723697B2 (ja) 2016-05-27 2023-04-19 抗ｔｉｍ－３抗体及びその使用方法

Publications (3)

Publication Number Publication Date
JP2019520809A JP2019520809A (ja) 2019-07-25
JP2019520809A5 JP2019520809A5 (enExample) 2020-07-09
JP7267012B2 true JP7267012B2 (ja) 2023-05-01

Family

ID=59014827

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018561979A Active JP7267012B2 (ja) 2016-05-27 2017-05-26 抗ｔｉｍ－３抗体及びその使用方法
JP2023068767A Active JP7723697B2 (ja) 2016-05-27 2023-04-19 抗ｔｉｍ－３抗体及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023068767A Active JP7723697B2 (ja) 2016-05-27 2023-04-19 抗ｔｉｍ－３抗体及びその使用方法

Country Status (16)

Country Link
US (5) US10639368B2 (enExample)
EP (1) EP3464360B1 (enExample)
JP (2) JP7267012B2 (enExample)
KR (3) KR102543118B1 (enExample)
CN (2) CN118359722A (enExample)
AU (2) AU2017271588B2 (enExample)
BR (1) BR112018074463A2 (enExample)
CA (1) CA3024508A1 (enExample)
MA (1) MA45123A (enExample)
MX (2) MX389710B (enExample)
MY (1) MY195089A (enExample)
NZ (2) NZ788279A (enExample)
PH (1) PH12018502400A1 (enExample)
SG (2) SG11201810023QA (enExample)
TW (2) TWI781934B (enExample)
WO (1) WO2017205721A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
CN116333153A (zh) 2014-11-26 2023-06-27 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10584167B2 (en) 2015-03-23 2020-03-10 Bayer Pharma Aktiengesellschaft Anti-CEACAM6 antibodies and uses thereof
MA45123A (fr) * 2016-05-27 2019-04-10 Agenus Inc Anticorps anti-tim-3 et leurs méthodes d'utilisation
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
AU2017297506A1 (en) 2016-07-14 2019-02-21 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
WO2019046321A1 (en) 2017-08-28 2019-03-07 Bristol-Myers Squibb Company TIM-3 ANTAGONISTS FOR THE TREATMENT AND DIAGNOSIS OF CANCERS
KR102813913B1 (ko) * 2018-01-12 2025-05-30 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체 및 그의 용도
EP3768725A4 (en) * 2018-03-20 2021-06-02 Wuxi Biologics Ireland Limited NEW ANTI-TIM-3 ANTIBODIES
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
CN112469477A (zh) * 2018-04-04 2021-03-09 Xencor股份有限公司 与成纤维细胞活化蛋白结合的异源二聚体抗体
WO2019196911A1 (en) * 2018-04-12 2019-10-17 Nanjing Leads Biolabs Co., Ltd. Antibody binding tim-3 and use thereor
CA3108812A1 (en) * 2018-08-20 2020-02-27 Jiangsu Hengrui Medicine Co., Ltd. Use of tim-3 antibody in preparation of medicines for treating tumors
CN109294987A (zh) * 2018-11-05 2019-02-01 中山大学附属第医院 一种非治疗目的的恢复浸润性t淋巴细胞免疫功能的方法
WO2020119719A1 (en) * 2018-12-12 2020-06-18 Wuxi Biologics (Shanghai) Co. Ltd. Anti-tim-3 antibodies and uses thereof
KR20210104704A (ko) 2018-12-19 2021-08-25 바이엘 악티엔게젤샤프트 항 ceacam6 및 tim3 항체의 제약 조합물
US11407828B2 (en) 2019-02-01 2022-08-09 Novarock Biotherapeutics, Ltd. Anti-CLauDiN 18 antibodies and methods of use thereof
WO2020222235A1 (en) * 2019-04-29 2020-11-05 4C Biomed Inc. Anti-hvem antibodies and use thereof
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
JP2022534982A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよびその使用
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
EP4204453A1 (en) 2020-08-31 2023-07-05 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
US20220233689A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Methods of treating tumors
RS66849B1 (sr) 2020-12-28 2025-06-30 Bristol Myers Squibb Co Kompozicije antitela i postupci njihove upotrebe
EP4083065A1 (en) 2021-01-28 2022-11-02 NantBio, Inc. Anti-tim3 monoclonal antibodies and chimeric antigen receptors
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
EP4326773A4 (en) 2021-04-23 2025-09-24 Suzhou Neologics Bioscience Co Ltd ANTIBODIES TARGETING TIM-3 AND THEIR USES
CA3230117A1 (en) 2021-09-02 2023-03-09 Mark Trautwein Anti-cecam6 antibodies with reduced side-effects
KR20240159621A (ko) 2022-03-18 2024-11-05 브리스톨-마이어스 스큅 컴퍼니 폴리펩티드를 단리하는 방법
CN114478778B (zh) * 2022-04-01 2022-06-28 中国人民解放军军事科学院军事医学研究院 抗Tim-3纳米抗体及其应用
AU2023281061A1 (en) 2022-06-02 2024-12-05 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025043111A2 (en) * 2023-08-23 2025-02-27 Forte Subsidiary, Inc. Multispecific immune cell engager
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011155607A1 (ja) 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
CN102492038A (zh) 2011-12-09 2012-06-13 中国人民解放军军事医学科学院基础医学研究所 抗人Tim-3的中和性单克隆抗体L3D及其用途
CN102490238A (zh) 2011-11-23 2012-06-13 东北林业大学 玉米秸秆皮瓤的分离方法
WO2015117002A1 (en) 2014-01-31 2015-08-06 Novartis Ag Antibody molecules to tim-3 and uses thereof

Family Cites Families (306)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
DE69427974T2 (de) 1993-04-29 2001-12-06 Unilever N.V., Rotterdam Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
DK1231268T3 (da) 1994-01-31 2005-11-21 Univ Boston Polyklonale antistofbiblioteker
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US6027947A (en) 1996-08-20 2000-02-22 Ramtron International Corporation Partially or completely encapsulated top electrode of a ferroelectric capacitor
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US6139865A (en) 1996-10-01 2000-10-31 Eurand America, Inc. Taste-masked microcapsule compositions and methods of manufacture
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6017540A (en) 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
EP1009429B1 (en) 1997-08-29 2009-07-08 Antigenics Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
EP0968711B9 (en) 1997-10-28 2008-05-28 Bando Chemical Industries, Ltd. Dermatological patch sheet and process for producing base sheet therefor
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
DK1104306T3 (da) 1998-08-10 2006-05-22 Antigenics Inc Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
AU5309600A (en) 1999-06-02 2000-12-18 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
ATE440111T1 (de) 1999-11-29 2009-09-15 Bac Ip B V Immobilisierte antigenbindende moleküle aus einer domäne
PT1234031T (pt) 1999-11-30 2017-06-26 Mayo Foundation B7-h1, uma nova molécula imunoregulatória
EP1125905A1 (en) 2000-02-16 2001-08-22 Pepscan Systems B.V. Segment synthesis
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
DK1272647T3 (en) 2000-04-11 2014-12-15 Genentech Inc Multivalent antibodies and uses thereof
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
WO2002066984A2 (en) 2001-02-16 2002-08-29 Pepscan Systems B.V. Arrays for determining binding of biomolecules
EP1406653A4 (en) 2001-06-29 2005-05-04 Univ Leland Stanford Junior T CELL REGULATION GENES AND METHOD OF USE THEREOF
US7838220B2 (en) 2001-06-29 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
AU2003303082B2 (en) 2002-01-30 2009-07-02 Dana-Farber Cancer Institute, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
AU2004280333A1 (en) 2003-08-22 2005-04-21 Medimmune, Llc Humanization of antibodies
US20050208627A1 (en) 2003-09-18 2005-09-22 Bowdish Katherine S Elicitation of antibodies to self peptides in mice by immunization with dendritic cells
EP1677824A2 (en) 2003-09-18 2006-07-12 Alexion Pharmaceuticals, Inc. Elicitation of antibodies to self peptides in mice by immunization with dendritic cells
BRPI0414924A (pt) 2003-10-03 2006-11-07 Brigham & Womens Hospital ligantes de tim-3 e seus métodos
CN101035561A (zh) 2004-03-24 2007-09-12 特罗斯药品公司 作为改善对疫苗的免疫反应的佐剂的组合物和使用方法
EA200601761A1 (ru) 2004-03-24 2007-06-29 Телос Фармасьютикалз, Инк. Композиции в качестве адъювантов для усиления иммунных ответов на вакцины и способы их применения
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
AU2005255024C1 (en) 2004-06-14 2010-09-09 The Board Of Trustees Of The University Of Illinois Antibodies binding to CD34+/CD36+ fetal but not to adult cells
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TWI323734B (en) 2005-08-19 2010-04-21 Abbott Lab Dual variable domain immunoglobulin and uses thereof
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
CA2668693A1 (en) 2006-11-15 2008-05-22 David E. Anderson Therapeutic uses of tim-3 modulators
AU2007331672A1 (en) 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
US20110020269A1 (en) 2007-05-08 2011-01-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
EP3176264B1 (en) 2007-05-30 2018-09-26 Postech Academy-Industry- Foundation Immunoglobulin fusion proteins
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2212350B1 (en) 2007-10-26 2013-08-28 Governing Council of the University of Toronto Treating chronic viral infection by targetting TIM-3
WO2009064290A1 (en) 2007-11-13 2009-05-22 Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Structure of tim family members
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
PT4160212T (pt) 2008-01-15 2024-06-25 Univ Leland Stanford Junior Marcadores de células estaminais de leucemia mielóide aguda
US20110059106A1 (en) 2008-01-29 2011-03-10 Brigham And Women's Hospital, Inc. Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
PL2242773T3 (pl) 2008-02-11 2017-11-30 Cure Tech Ltd. Przeciwciała monoklonalne do leczenia nowotworu
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2009120905A2 (en) 2008-03-26 2009-10-01 Cellerant Therapeutics, Inc. Immunoglobulin and/or toll-like receptor proteins associated with myelogenous haematological proliferative disorders and uses thereof
WO2009131572A1 (en) 2008-04-22 2009-10-29 Government Of The U.S. As Represented By The Secretary Of The Department Of Health And Human Service Structure of tim family members
SG192485A1 (en) 2008-07-08 2013-08-30 Incyte Corp 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
EP2927240A1 (en) 2008-08-25 2015-10-07 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
EP2342229A1 (en) 2008-09-12 2011-07-13 ISIS Innovation Limited Pd-1 specific antibodies and uses thereof
ES2592216T3 (es) 2008-09-26 2016-11-28 Dana-Farber Cancer Institute, Inc. Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010084999A1 (en) 2009-01-26 2010-07-29 Protegene, Inc. Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases
WO2010110346A1 (ja) 2009-03-24 2010-09-30 独立行政法人理化学研究所 白血病幹細胞マーカー
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
MX368932B (es) 2009-06-26 2019-10-22 Regeneron Pharma Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original.
CA2771336C (en) 2009-09-15 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
WO2011100841A1 (en) 2010-02-16 2011-08-25 Valorisation-Recherche, Limited Partnership Pd-1 modulation and uses thereof for modulating hiv replication
IL300733B1 (en) 2010-03-05 2025-10-01 Univ Johns Hopkins Compositions and methods for antibodies and fusion proteins targeted for immune modulation
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
WO2012088302A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
US9555108B2 (en) 2011-03-24 2017-01-31 Texas Tech University System TCR mimic antibodies as vascular targeting tools
JP6082997B2 (ja) 2011-04-01 2017-02-22 メモリアル スローン−ケタリング キャンサー センター Ｈｌａ−ａ２により提示されるｗｔ１ペプチドへのｔ細胞受容体様抗体
PL2699264T3 (pl) 2011-04-20 2018-08-31 Medimmune, Llc Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
WO2012177788A1 (en) 2011-06-20 2012-12-27 La Jolla Institute For Allergy And Immunology Modulators of 4-1bb and immune responses
EP2723381A4 (en) 2011-06-21 2015-03-18 Univ Johns Hopkins FOCUSED RADIATION FOR THE REINFORCEMENT OF IMMUNE TREATMENTS AGAINST NEOPLASMS
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
LT2734551T (lt) 2011-07-24 2018-04-10 Cure Tech Ltd. Humanizuotų imunomoduliuojančių monokloninių antikūnų variantai
US8920075B2 (en) 2011-09-01 2014-12-30 Halo Maritime Defense Systems, Inc. Marine barrier and gate
EP2785375B1 (en) 2011-11-28 2020-07-22 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
KR20140126357A (ko) 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
WO2013124327A1 (en) 2012-02-21 2013-08-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Tim receptors as virus entry cofactors
WO2013126809A1 (en) 2012-02-23 2013-08-29 Sloan-Kettering Institute For Cancer Research Prediction of responsiveness to treatment with immunomodulatory therapeutics and method of monitoring abscopal effects during such treatment
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
CN104736168B (zh) 2012-05-31 2018-09-21 索伦托治疗有限公司 与pd-l1结合的抗原结合蛋白
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
EP2879498A4 (en) 2012-07-30 2016-03-30 Alex Wah Hin Yeung BY TREATMENT OF AT LEAST TWO OR ALL THREE OF THE FOLLOWING COMPONENTS SUCH AS TUMOR CELLS, AN ONCOLYTIC VIRUS VECTOR WITH TRANSGENIC EXPRESSION OF GM-CSF AND AN IMMUNE TEST MODULE DEVELOPED TUMOR SPECIFIC LIVING AND IN VIVO CANCER VACCINE SYSTEM
CA2916638C (en) 2012-07-31 2021-01-12 The Brigham And Women's Hospital, Inc. Modulation of the immune response
US9845356B2 (en) 2012-08-03 2017-12-19 Dana-Farber Cancer Institute, Inc. Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use
JP6461800B2 (ja) 2012-10-04 2019-01-30 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ヒトモノクローナル抗ｐｄ−ｌ１抗体および使用方法
DK2925350T3 (da) 2012-12-03 2019-05-13 Bristol Myers Squibb Co Øgning af virksomheden mod cancer af immunomodulatoriske fc- fusionsproteiner
US11116818B2 (en) 2012-12-13 2021-09-14 Children's Medical Center Corporation Dana-Farber Cancer Institute Compositions and methods for inhibiting viral entry
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
HRP20210122T1 (hr) 2013-05-02 2021-04-16 Anaptysbio, Inc. Protutijela usmjerena protiv programirane smrti-1 (pd-1)
CN111423511B (zh) 2013-05-31 2024-02-23 索伦托药业有限公司 与pd-1结合的抗原结合蛋白
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
CN105682683A (zh) 2013-08-02 2016-06-15 阿杜罗生物科技控股有限公司 结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
WO2015035112A1 (en) 2013-09-05 2015-03-12 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
WO2015036394A1 (en) 2013-09-10 2015-03-19 Medimmune Limited Antibodies against pd-1 and uses thereof
ES2792183T3 (es) 2013-09-13 2020-11-10 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
US10202454B2 (en) 2013-10-25 2019-02-12 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
JP6508785B2 (ja) 2013-10-25 2019-05-08 ファーマサイクリックス エルエルシー ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
CN104558177B (zh) 2013-10-25 2020-02-18 苏州思坦维生物技术股份有限公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
KR20160093012A (ko) 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물
PE20160953A1 (es) 2013-12-12 2016-09-26 Shanghai hengrui pharmaceutical co ltd Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
CN119775416A (zh) 2013-12-24 2025-04-08 杨森制药公司 抗vista抗体及片段
CN105263521B (zh) 2014-01-15 2021-06-29 卡德门企业有限公司 免疫调节剂
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
CN105979961B (zh) 2014-02-05 2020-12-18 西达-赛奈医疗中心 用于治疗癌症和感染性疾病的方法和组合物
SG11201606577YA (en) 2014-02-10 2016-09-29 Merck Patent Gmbh TARGETED TGFβ INHIBITION
WO2017042633A2 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
ES3040431T3 (en) 2014-03-12 2025-10-31 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
EP2939690A1 (en) 2014-04-29 2015-11-04 Medizinische Hochschule Hannover Vaccine
US10682400B2 (en) 2014-04-30 2020-06-16 President And Fellows Of Harvard College Combination vaccine devices and methods of killing cancer cells
US11505605B2 (en) 2014-05-13 2022-11-22 Chugai Seiyaku Kabushiki Kaisha T cell-redirected antigen-binding molecule for cells having immunosuppression function
SMT202100116T1 (it) * 2014-05-28 2021-05-07 Agenus Inc Anticorpi anti-gitr e metodi di utilizzo degli stessi
US9885721B2 (en) 2014-05-29 2018-02-06 Spring Bioscience Corporation PD-L1 antibodies and uses thereof
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
EP3161003A2 (en) 2014-06-27 2017-05-03 Apogenix GmbH Combination of cd95/cd95l inhibition and cancer immunotherapy
WO2015200828A1 (en) 2014-06-27 2015-12-30 H. Lee Moffit Cancer Center And Research Institute, Inc. Conjugates for immunotherapy
CN106604742B (zh) 2014-07-03 2019-01-11 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
AU2015287969B2 (en) 2014-07-07 2020-07-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer
CN112546231A (zh) 2014-07-09 2021-03-26 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
JP6843736B2 (ja) 2014-07-16 2021-03-17 トランジェーヌＴｒａｎｓｇｅｎｅ 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
CA2957258C (en) 2014-08-05 2023-11-07 MabQuest SA Immunological reagents
US10087257B2 (en) 2014-08-08 2018-10-02 The Board Of Trustees Of The Leland Stanford Junior University SIRP alpha-antibody fusion proteins
WO2016020538A1 (en) 2014-08-08 2016-02-11 Transgene Sa Hbv vaccine and antibody combination therapy to treat hbv infections
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
KR102050082B1 (ko) 2014-08-19 2019-11-29 머크 샤프 앤드 돔 코포레이션 항-tigit 항체
AU2015308527C1 (en) 2014-08-29 2021-07-15 F. Hoffmann-La Roche Ag Combination therapy of tumor-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
EA201790737A1 (ru) 2014-10-03 2017-08-31 Новартис Аг Комбинированная терапия
MX391478B (es) 2014-10-10 2025-03-21 Idera Pharmaceuticals Inc Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cáncer.
RU2716821C2 (ru) 2014-10-24 2020-03-17 Калиди Биотерапьютикс, Инк. Комбинированный иммунотерапевтический подход к лечению рака
SG11201703403TA (en) * 2014-10-27 2017-05-30 Agency Science Tech & Res Anti-tim-3 antibodies
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
CN107001475B (zh) * 2014-11-06 2021-01-29 豪夫迈·罗氏有限公司 抗tim3抗体及使用方法
CA2966660A1 (en) 2014-11-13 2016-05-19 The Johns Hopkins University Checkpoint blockade and microsatellite instability
LT3789402T (lt) 2014-11-20 2022-09-26 F. Hoffmann-La Roche Ag Kompleksinė terapija, naudojant t ląsteles aktyvinančias bispecifines antigeną surišančias molekules ir pd-1 ašį surišančius antagonistus
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
HRP20201756T8 (hr) 2014-11-21 2021-08-20 Bristol-Myers Squibb Company Antitijela koja sadrže modificirane regije teškog lanca
AU2015357463B2 (en) 2014-12-05 2021-10-07 Immunext, Inc. Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
JP2018502123A (ja) 2015-01-20 2018-01-25 イミューンエクサイト， インコーポレイテッド 癌免疫療法のための組成物及び方法
KR20240132103A (ko) 2015-01-29 2024-09-02 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 관문 억제제 및 백신 조합 및 면역요법을 위한 이들의 사용
ES2926384T3 (es) 2015-02-06 2022-10-25 Nat Univ Singapore Métodos para mejorar la eficacia de células inmunitarias terapéuticas
WO2016128542A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
CN104592388B (zh) * 2015-03-02 2017-05-31 中国人民解放军总医院 一种抗人Tim‑3的单克隆抗体的抗原结合部分
EP3265486A4 (en) 2015-03-06 2018-11-14 Sorrento Therapeutics, Inc. Antibody therapeutics that bind tim3
JP2018512396A (ja) 2015-03-09 2018-05-17 キングス・カレッジ・ロンドン Ｔｈ１応答を増強するためのｒａｒアルファアゴニストを用いた併用療法
CA2984624A1 (en) 2015-03-18 2016-09-22 Baylor College Of Medicine Her2/erbb2 chimeric antigen receptor
EP3273944B1 (en) 2015-03-25 2024-11-20 The Regents of The University of Michigan Compositions and methods for delivery of biomacromolecule agents
US20180085398A1 (en) 2015-03-30 2018-03-29 Dana-Farber Cancer Institute, Inc. Compositions and methods of treating cancer
SG10201909173PA (en) 2015-04-01 2019-11-28 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
WO2016171722A1 (en) 2015-04-24 2016-10-27 The Brigham And Women's Hospital, Inc. Interactions between ceacam and tim family members
US20180153986A1 (en) 2015-04-24 2018-06-07 The Brigham And Women's Hospital, Inc. Interactions between ceacam and tim family members
WO2016176761A1 (en) 2015-05-01 2016-11-10 Immunovaccine Technologies Inc., Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines
WO2016179194A1 (en) 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
WO2016180781A1 (en) 2015-05-08 2016-11-17 Michele Maio Combination therapy of mesothelioma
IL293135A (en) 2015-05-13 2022-07-01 Agenus Inc Composition comprising at least two different complexes of a purified stress protein bound to an antigenic peptide
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
HK1252026A1 (zh) 2015-06-11 2019-05-10 Bionomics Limited 药物组合及其应用
HUE066300T2 (hu) 2015-06-24 2024-07-28 Janssen Biotech Inc Immunmoduláció és szolid tumorok kezelése CD38-hoz specifikusan kötõdõ antitestekkel
WO2017013419A1 (en) 2015-07-20 2017-01-26 Virttu Biologics Limited Use of oncolytic herpes simplex virus, alone or in combination with immune checkpoint inhibitor, in the treatment of cancer
WO2017019767A1 (en) 2015-07-27 2017-02-02 Myosotis, Llc Inhibition of CXCL12 in Cancer Immunotherapy
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20180221508A1 (en) 2015-07-31 2018-08-09 Tarveda Therapeutics, Inc. Compositions and methods for immunomodulation
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
US20180230431A1 (en) 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
WO2017025496A1 (en) 2015-08-12 2017-02-16 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer
US10766957B2 (en) 2015-08-14 2020-09-08 Merck Sharp & Dohme Corp Anti-TIGIT antibodies
WO2017031242A1 (en) 2015-08-20 2017-02-23 Sutro Biopharma, Inc. Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
US20180244783A1 (en) 2015-08-31 2018-08-30 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
EP3353210B8 (en) 2015-09-25 2024-12-18 F. Hoffmann-La Roche AG Anti-tigit antibodies and methods of use
SG10201912736UA (en) 2015-10-01 2020-02-27 Potenza Therapeutics Inc Anti-tigit antigen-binding proteins and methods of use thereof
WO2017055393A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
KR20180081507A (ko) 2015-10-02 2018-07-16 다나-파버 캔서 인스티튜트 인크. 브로모도메인 저해제와 관문 차단의 조합 요법
PE20180773A1 (es) 2015-10-02 2018-05-07 Hoffmann La Roche Anticuerpos biespecificos para pd1 y tim3
ES2994611T3 (en) 2015-10-19 2025-01-27 Cg Oncology Inc Methods of treating solid or lymphatic tumors by combination therapy
HK1258509A1 (zh) 2015-10-22 2019-11-15 Ablynx Nv Gitr激动剂
SI3370768T1 (sl) 2015-11-03 2022-04-29 Janssen Biotech, Inc. Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe
US20180346571A1 (en) 2015-11-17 2018-12-06 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
UY37030A (es) * 2015-12-18 2017-07-31 Novartis Ag Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
MA45123A (fr) * 2016-05-27 2019-04-10 Agenus Inc Anticorps anti-tim-3 et leurs méthodes d'utilisation
CA3037380A1 (en) * 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
MA46770A (fr) 2016-11-09 2019-09-18 Agenus Inc Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
EP4536277A2 (en) * 2022-06-07 2025-04-16 Incyte Corporation Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011155607A1 (ja) 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
CN102490238A (zh) 2011-11-23 2012-06-13 东北林业大学 玉米秸秆皮瓤的分离方法
CN102492038A (zh) 2011-12-09 2012-06-13 中国人民解放军军事医学科学院基础医学研究所 抗人Tim-3的中和性单克隆抗体L3D及其用途
WO2015117002A1 (en) 2014-01-31 2015-08-06 Novartis Ag Antibody molecules to tim-3 and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH，2011年11月，Vol. 71, No. 21，pp. 6567-6571

Also Published As

Publication number Publication date
KR20230091191A (ko) 2023-06-22
MX2022001222A (es) 2022-03-02
JP2023083455A (ja) 2023-06-15
US12011481B2 (en) 2024-06-18
US10912828B2 (en) 2021-02-09
AU2022200658A1 (en) 2022-02-24
MX2018014387A (es) 2019-03-14
SG11201810023QA (en) 2018-12-28
CN109476751A (zh) 2019-03-15
MA45123A (fr) 2019-04-10
KR20190021224A (ko) 2019-03-05
CA3024508A1 (en) 2017-11-30
TW201803903A (zh) 2018-02-01
CN109476751B (zh) 2024-04-19
US20210252139A1 (en) 2021-08-19
NZ788279A (en) 2025-09-26
BR112018074463A2 (pt) 2019-03-06
EP3464360A1 (en) 2019-04-10
JP7723697B2 (ja) 2025-08-14
NZ749355A (en) 2023-04-28
TW202244062A (zh) 2022-11-16
WO2017205721A1 (en) 2017-11-30
EP3464360B1 (en) 2025-11-12
KR102543118B1 (ko) 2023-06-14
AU2017271588B2 (en) 2022-01-20
KR102366813B1 (ko) 2022-02-24
US20240181048A1 (en) 2024-06-06
CN118359722A (zh) 2024-07-19
AU2017271588A1 (en) 2019-01-17
KR20220025948A (ko) 2022-03-03
US11839653B2 (en) 2023-12-12
JP2019520809A (ja) 2019-07-25
MY195089A (en) 2023-01-10
US20200297841A1 (en) 2020-09-24
PH12018502400A1 (en) 2019-04-08
AU2022200658B2 (en) 2025-05-08
EP3464360C0 (en) 2025-11-12
US20200282050A1 (en) 2020-09-10
TWI895621B (zh) 2025-09-01
SG10201912563XA (en) 2020-02-27
MX389710B (es) 2025-03-20
US20170368168A1 (en) 2017-12-28
US10639368B2 (en) 2020-05-05
TWI781934B (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
JP7723697B2 (ja) 抗ｔｉｍ－３抗体及びその使用方法
JP7297672B2 (ja) 抗ｃｄ１３７抗体およびその使用方法
CN110023337B (zh) 抗lag-3抗体及其使用方法
CN114585644A (zh) 抗cd96抗体及其使用方法
HK40076263A (en) Anti-cd96 antibodies and methods of use thereof
EA043100B1 (ru) Антитела против tim-3 и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200526

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230320

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230419

R150 Certificate of patent or registration of utility model

Ref document number: 7267012

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150